Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan
Auto-generated profile, based on publicly available information
Yuka Niwa
Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated transformative efficacy in HER2-positive metastatic breast cancer (MBC), and induction–maintenance strategies with T-DXd are under investigation to optimize the treatments. Understanding the time to maximal response (TTMR) is important for optimizing induction duration. However, real-world data on TTMR with T-DXd remain limited.Methods: TRACE is a multicenter, retrospective observational study. Patients with histologically confirmed HER2-positive MBC who received T-DXd between 2020 and 2025 were eligible. The primary endpoint was TTMR, defined as the time from T-DXd initiation to the nadir of target lesion sum of diameters, assessed according to RECIST v1.1. Patients with progressive disease as best overall response, stable disease without tumor shrinkage, or no evaluable target lesions were excluded.Results: Of 125 patients identified, 93 were eligible for the primary analysis. The median age was 60 years; 62% had hormone receptor-positive disease, and 66% received T-DXd in the third line or later. The median TTMR was 4.57 months (95% CI: 3.73–5.60). No significant difference in TTMR was observed by subgroups. Best overall response was CR in 9%, PR in 74%, and SD in 17%. Spider plot analysis showed a median tumor burden change of −2.7% beyond 18 weeks.Conclusions: In this real-world multicenter cohort, T-DXd achieved maximal tumor shrinkage at a median of 4.57 months in patients with HER2-positive MBC. Tumor burden change beyond 18 weeks was minimal at the population level, suggesting limited additional benefit from continued T-DXd. These findings may inform future maintenance strategies in HER2-positive MBC.